295 related articles for article (PubMed ID: 37920473)
1. T cell biology in neuromuscular disorders: a focus on Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis.
Lemos JP; Tenório LPG; Mouly V; Butler-Browne G; Mendes-da-Cruz DA; Savino W; Smeriglio P
Front Immunol; 2023; 14():1202834. PubMed ID: 37920473
[TBL] [Abstract][Full Text] [Related]
2. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
Long C; Amoasii L; Bassel-Duby R; Olson EN
JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
[TBL] [Abstract][Full Text] [Related]
3. MONITORING OF RENAL, HEPATIC AND IMMUNE FUNCTION INDICES IN PATIENTS WITH NEUROMUSCULAR DISORDERS: AMYOTROPHIC LATERAL SCLEROSIS AND DUCHENNE MUSCULAR DYSTROPHY.
Kononets O; Karaiev T; Lichman L; Kucher O; Kononets O
Georgian Med News; 2022 Jan; (322):131-139. PubMed ID: 35134775
[TBL] [Abstract][Full Text] [Related]
4. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
5. When should home mechanical ventilation be started in patients with different neuromuscular disorders?
Dreher M; Rauter I; Storre JH; Geiseler J; Windisch W
Respirology; 2007 Sep; 12(5):749-53. PubMed ID: 17875066
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy flexes muscle.
VandenDriessche T
J Gene Med; 2005 Sep; 7(9):1255-6. PubMed ID: 15991258
[TBL] [Abstract][Full Text] [Related]
7. A quantitative study of the muscle satellite cells in various neuromuscular disorders.
Ishimoto S; Goto I; Ohta M; Kuroiwa Y
J Neurol Sci; 1983 Dec; 62(1-3):303-14. PubMed ID: 6668477
[TBL] [Abstract][Full Text] [Related]
8. On the path to a Duchenne muscular dystrophy therapy.
Fallon J
R I Med J (2013); 2013 Feb; 96(2):22-5. PubMed ID: 23641422
[TBL] [Abstract][Full Text] [Related]
9. RNA-targeted splice-correction therapy for neuromuscular disease.
Wood MJ; Gait MJ; Yin H
Brain; 2010 Apr; 133(Pt 4):957-72. PubMed ID: 20150322
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update.
Sun C; Shen L; Zhang Z; Xie X
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32717791
[TBL] [Abstract][Full Text] [Related]
11. Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS).
Wada A; Kawakami M; Liu M; Otaka E; Nishimura A; Liu F; Otsuka T
J Neurol; 2015 Oct; 262(10):2225-31. PubMed ID: 26142025
[TBL] [Abstract][Full Text] [Related]
12. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Pulmonary Functions at Onset of Ventilatory Insufficiency in Patients With Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, and Myotonic Muscular Dystrophy.
Cho HE; Lee JW; Kang SW; Choi WA; Oh H; Lee KC
Ann Rehabil Med; 2016 Feb; 40(1):74-80. PubMed ID: 26949672
[TBL] [Abstract][Full Text] [Related]
14. Provision and financing of assistive technology devices in Germany: a bureaucratic odyssey? The case of amyotrophic lateral sclerosis and Duchenne muscular dystrophy.
Henschke C
Health Policy; 2012 May; 105(2-3):176-84. PubMed ID: 22349416
[TBL] [Abstract][Full Text] [Related]
15. Nutritional assessment of patients with neuromuscular diseases.
Pessolano FA; Súarez AA; Monteiro SG; Mesa L; Dubrovsky A; Roncoroni AJ; De Vito EL
Am J Phys Med Rehabil; 2003 Mar; 82(3):182-5. PubMed ID: 12595769
[TBL] [Abstract][Full Text] [Related]
16. [Amyotrophic lateral sclerosis, myasthenia gravis, Duchenne muscular dystrophy or also a questionable disposition to malignant hyperthermia … : Systematics of anesthesiological management in neuromuscular diseases].
Kleinschmidt S
Anaesthesist; 2020 Jun; 69(6):371-372. PubMed ID: 32504160
[No Abstract] [Full Text] [Related]
17. The progress of AAV-mediated gene therapy in neuromuscular disorders.
Aguti S; Malerba A; Zhou H
Expert Opin Biol Ther; 2018 Jun; 18(6):681-693. PubMed ID: 29781327
[TBL] [Abstract][Full Text] [Related]
18. [Development of therapies against neuromuscular diseases causing muscle atrophy].
Tsuchida K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):229-33. PubMed ID: 17240849
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Changes of Tongue Thickness and Tongue Pressure in Neuromuscular Disorders.
Umemoto G; Fujioka S; Arahata H; Sakae N; Sasagasako N; Toda M; Furuya H; Tsuboi Y
BMC Neurol; 2021 Aug; 21(1):302. PubMed ID: 34353291
[TBL] [Abstract][Full Text] [Related]
20. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Choi E; Koo T
Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
